Mycobacterium abscessus, a notorious pathogen known for its resistance to most antibiotics, poses significant treatment challenges. To overcome this intrinsic resistance, a recent study published in Antimicrobial Agents and Chemotherapy by researchers from the University of Science and Technology of China and collaborators identified a promising molecular target that may guide the development of new therapeutic strategies.
Researchers have altered the genetic code in a strain of Escherichia coli, reducing the number of stop codons from three to one and assigning the freed-up stop codons to nonstandard amino acids. They reported on the recoded bacterium, which they named OCHRE, in Nature on Feb. 5, 2025.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, Alzheimer’s disease, overweight and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker.
Ubiquitin-specific protease 7 (USP7) is involved in DNA repair and cell cycle progression and, due to its control over the ubiquitination of key proteins, may impact oncogenes like MDM2 and c-Myc, as well as tumor suppressors such as p53 and p21.
Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr expression in lung mesenchymal cells. To do that, they used a Lepr(creERT2) mouse model tracing LEPR+ alveolar fibroblasts during neonatal alveologenesis.
RSS
